Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allogene Therapeutics, Inc.ALLO · Entity 5243 | SVP, Finance | August 10, 2023 | August 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allogene Therapeutics, Inc.
Report date August 10, 2023 · Filed August 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,881 |
Reported balance
After 2023-08-10 transaction · row 1
1 source rowRow 1 · 2023-08-10 · Grant · Acquired 11,401 · Balance 88,881 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2033-08-10 | Direct | 39,160 |
Reported balance
After 2023-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-10 · Grant · Acquired 39,160 · Balance 39,160 F1: 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2023 Filed Aug 14, 2023 23:59 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantStock Option (Right to Buy) · Derivative | 39,160 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001593968-23-001182 · primary_01.xml · derivative · entry 2 CHEN YINLIN JACK · CIK 0001989926 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,160 Underlying: Common Stock · 39,160 shares Expires 2033-08-10 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on August 10, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 23:59 UTC | Allogene Therapeutics, Inc. ALLO · Entity 5243 | GrantCommon Stock | 11,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001182 · primary_01.xml · nonDerivative · entry 1 CHEN YINLIN JACK · CIK 0001989926 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,881 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.